Table 1 Prevalence of P. hominis infection in the control population and gastrointestinal cancer patients
From: High prevalence of Pentatrichomonas hominis infection in gastrointestinal cancer patients
Group | No. examined | No. positive (%) | No. negative (%) | χ2/df/P-value | Logistic regression analysis | ||
|---|---|---|---|---|---|---|---|
ORa | 95% CI | P-value | |||||
Control | 142 | 13 (9.15) | 129 (90.85) | Reference | 1 | Reference | – |
Gastrointestinal cancer | 195 | 81 (41.54) | 114 (58.46) | 42.84/1/< 0.001 | 6.75 | 3.55–12.83 | < 0.001 |
Cancer types | |||||||
 Colorectal cancer | 116 | 44 (37.93) | 72 (62.07) | 30.72/1/< 0.001 | 5.93 | 3.00–11.77 | < 0.001 |
 Stomach cancer | 51 | 23 (45.1) | 28 (54.9) | 31.95/1/< 0.001 | 7.11 | 3.13–16.11 | < 0.001 |
 Esophageal cancer | 16 | 7 (43.75) | 9 (56.25) | 12.59/1/< 0.001b | 34.85 | 5.94–204.40 | < 0.001 |
 Liver cancer | 7 | 4 (57.14) | 3 (42.86) | 10.82/1/0.001b | 20.38 | 3.29–126.28 | 0.001 |
 Small intestine cancer | 5 | 3 (60) | 2 (40) | –/–/0.009 (OR: 14.88; CI: 0.82–4.58)c | 14.77 | 1.03–211.18 | 0.047 |